



About OMICS Group

OMICS Group International is an amalgamation of [Open Access publications](#) and worldwide international science conferences and events. Established in the year 2007 with the sole aim of making the information on Sciences and technology 'Open Access', OMICS Group publishes 400 online open access [scholarly journals](#) in all aspects of Science, Engineering, Management and Technology journals. OMICS Group has been instrumental in taking the knowledge on Science & technology to the doorsteps of ordinary men and women. Research Scholars, Students, Libraries, Educational Institutions, Research centers and the industry are main stakeholders that benefitted greatly from this knowledge dissemination. OMICS Group also organizes 300 [International conferences](#) annually across the globe, where knowledge transfer takes place through debates, round table discussions, poster presentations, workshops, symposia and exhibitions.



About OMICS Group Conferences

OMICS Group International is a pioneer and leading science event organizer, which publishes around 400 open access journals and conducts over 300 Medical, Clinical, Engineering, Life Sciences, Pharma scientific conferences all over the globe annually with the support of more than 1000 scientific associations and 30,000 editorial board members and 3.5 million followers to its credit.

OMICS Group has organized 500 conferences, workshops and national symposiums across the major cities including San Francisco, Las Vegas, San Antonio, Omaha, Orlando, Raleigh, Santa Clara, Chicago, Philadelphia, Baltimore, United Kingdom, Valencia, Dubai, Beijing, Hyderabad, Bengaluru and Mumbai.

Proteomics aspects of Moroccan cases with Alzheimer's Disease.

Nadia El Kadmiri

Nadia El Kadmiri^{1,2,3}, Raquel Cuardos⁴, Bouchra El Moutawakil^{1,3}, Ilham Slassi^{1,3}, Jesus Avila⁴, Sellama Nadifi¹, Ahmed Hachem⁵, Abdelaziz Soukri²

¹ Laboratory of Medical Genetics and Molecular Pathology, Faculty of Medicine and Pharmacy, University Hassan II, Casablanca, Morocco.

² Laboratory of Physiology and Molecular Genetics, Faculty of Sciences Ain Chock, University Hassan II, Casablanca, Morocco.


³ Department of Neurology CHU IBN ROCHD, Casablanca, Morocco.

⁴ CIBERNED – Investigations Center of Neurodegenerative Diseases- the Centro de Biología Molecular “Severo Ochoa” Madrid, Spain.

⁵ Laboratory of Thrombosis and Hemostasis, Montreal Heart Institute, Montreal, Quebec, Canada.


Introduction

- Alzheimer's disease (AD) is the most common cause of dementia in the elderly. Clinically characterized by :




Introduction

www.neuro-one.fr




Neurofibrillar tangles (Tau pathology)



Neurone

sénile plaques (A β pathology)



Dégénérescence neurofibrillaire

Corps cellulaire


Introduction

Table 1 : Genetic factors

Chromosome	gene	% due to mutation	Age of Onset	Form of AD
21	APP	0,4%	45-60	Early-Onset Familial AD (EOAD) /autosomal dominant inheritance)
14	PS1	5,6%	35-60	
1	PS2	0,1%	35-60	
19	ApoE ε4	65%	>55	late-onset form of AD(LOAD)/Risk factor
Others : Chrom 11: Sortilin receptor Chrom 8 : Clusterin Chrom 1 : Complement component receptor 1				Risk Factors


Introduction

Hyperphosphorylation the microtubule-associated protein tau.



Introduction

GAPDH enzyme




Introduction

Other GAPDH Functions



Introduction

Involvement of GAPDH in cellular pathologies





GAPDH and MA


- The potential involvement of glyceraldehyde-3-phosphate dehydrogenase (GAPDH; EC 1.2.1.12) in neurodegeneration by reporting a non-glycolytic activity of GAPDH specifically in brains of AD cases.
- GAPDH strongly interacts with the β -amyloid precursor protein (β -APP) with high affinity in vitro.

Aim of study

✿ In this study we aimed :

- To probe for the role of GAPDH and its interaction with A β amyloid aggregates especially in blood samples from Moroccan patient of FAD cases carrying frameshift mutations in the presenilin genes.

Methods




Results

J Mol Neurosci
DOI 10.1007/s12031-014-0374-8

A Proteomic Approach for the Involvement of the GAPDH in Alzheimer Disease in the Blood of Moroccan FAD Cases

Nadia El Kadmiri · Raquel Cuardos ·
Bouchra El Moutawakil · Ilham Slassi · Jesus Avila ·
Sellama Nadifi · Ahmed Hachem · Abdelaziz Soukri























Results

J Mol Neurosci
DOI 10.1007/s12031-014-0374-8

A Proteomic Approach for the Involvement of the GAPDH in Alzheimer Disease in the Blood of Moroccan FAD Cases

Nadia El Kadmiri · Raquel Cuados ·
Bouchra El Moutawakil · Ilham Slassi · Jesus Avila ·
Sellama Nadifi · Ahmed Hachem · Abdelaziz Soukri


	Brain specimen of AD	Brain specimen of healthy control	Brain specimen of Mutant tau transgenic mice	Brain specimen of Wild type mice	Blood of Mutant tau transgenic mice	Blood of Wild type mice	Blood of healthy subject	Blood of FAD (F3)	Blood of FAD (F2)	Blood of FAD (F1)
β -Actin (Control) (42 kDa)										
GAPDH Expression (37 kDa)										

Results

J Mol Neurosci
DOI 10.1007/s12031-014-0374-8

A Proteomic Approach for the Involvement of the GAPDH in Alzheimer Disease in the Blood of Moroccan FAD Cases

Nadia El Kadmiri · Raquel Cuardos ·
Bouchra El Moutawakil · Ilham Slassi · Jesus Avila ·
Sellama Nadifi · Ahmed Hachem · Abdelaziz Soukri




Representative dot blot of formed A β aggregates. Protein extracts from peripheral blood from two FAD cases (F1 and F2) and two control individuals (C1 and C2) were incubated with A β and then transferred onto nitrocellulose membranes. Membrane were then blotted for A β to assess the potential of the protein extracts to induce accumulation of A β aggregates.

Results

J Mol Neurosci
DOI 10.1007/s12031-014-0374-8

A Proteomic Approach for the Involvement of the GAPDH in Alzheimer Disease in the Blood of Moroccan FAD Cases

Nadia El Kadmiri · Raquel Cuardos ·
Bouchra El Moutawakil · Ilham Slassi · Jesus Avila ·
Sellama Nadifi · Ahmed Hachem · Abdelaziz Soukri



Representative electron microscopy images of formed A β aggregates. Protein extracts from (A) protein extracts from brain specimens from a confirmed AD case at autopsy, (B) protein extracts of peripheral blood from a FAD case (ID. F1), (C) protein extracts from peripheral blood from a FAD case (ID.F2), (D) protein extracts from brain specimens from a healthy subject at autopsy, (E) protein extracts from peripheral blood from a healthy subject and (F) PBS as control were incubated with A β and then visualized on an electron microscopic to assess amyloid fibril formation. (A), (B) and (C) show significant amyloid fibrils formation, whereas (D), (E) and (F) show no abnormalities. The scale bar for images (A), (B), (C) and (D) represents 70 nm, whereas that for images (E) and (F) represents 100 nm.



Discussion

- Our findings show a significant decrease in GAPDH activity albeit unchanged protein expression in the brain of both mutant tau transgenic mice and FAD case, which may be due to post-translational alterations.
- the expression of GAPDH in the blood of mutant tau transgenic mice and our FAD cases was decreased in comparison to controls, probably due to an alteration at the transcriptional level.



Discussion

- Dot blotting showed increased $A\beta$ accumulation in peripheral blood from our FAD cases but not in healthy controls. EM examination revealed significant amyloid fibrils formation both in brain specimens from confirmed AD case and in peripheral blood from our FAD cases, who carry frameshift mutations located in presenilin genes



Discussion

- We can conclude that there is a link between amyloid aggregation and GAPDH through conversion of the normal conformation of GAPDH to an abnormal one, which leads to a decrease in its activity.
- Our mutational and proteomic analysis report a correlation between genotype and phenotype in our cases of EOAD involving the frameshift presenilin mutations and suggest that these mutations increase the risk of developing neurodegenerative diseases through $A\beta$ -42 accumulation, which is due to modulation in the proteolytic processing of APP.

Perspective

- To clarify this decreased expression of GAPDH observed in the blood compared to brain.




Collaboration



Acknowledgments

Staff at the Universita Catholica in Rome, Italy



RANBAXY MOROCCO LLC





Thank you





Let Us Meet Again

We welcome you all to our future conferences of
OMICS Group International

Please Visit:

www.omicsgroup.com

www.conferenceseries.com

www.proteomicsconference.com